Navigation Links
Study examines how breastfeeding impacts cost of care for very low birth weight infants
Date:12/16/2008

(CHICAGO) The National Institutes of Health (NIH) has awarded nearly $3 million to support Rush University Medical Center's study analyzing how human breast milk impacts the health outcomes and health care cost savings for very low birth weight infants babies less than 1500 grams.

The grant will enable researchers at Rush to conduct a five-year study involving the largest prospective cohort of 600 very low birth weight infants born to racially and economically diverse mothers. The study will have a representative number of African American and low income women enrolled in this study.

"Unlike other institutions with the same demographics, the mothers that give birth at Rush elect to provide breast milk because they are encouraged to think of their milk as 'medicine' for their babies," said Paula Meier, director of clinical research and lactation in the Rush neonatal intensive care unit (NICU) and principal investigator of the study.

More than 95 percent of very low birth weight infants in Rush's NICU receive their mothers' breast milk and will be enrolled into the study.

The trial will examine the relationship between the amount, the duration, and the timing of human milk feedings and improved health outcomes for very low birth weight babies hospitalized in the NICU.

Past research indicates that human milk protects very low birth weight infants from prematurity-specific complications that predispose these infants to short-and long-term health problems and increase cost of health care.

"However, no one has conclusively linked the amount and length of time these infants need to be fed human milk in order to lower their health risks and tie it back to cost of care," said Meier.

"For this patient population, human milk is much more important for its therapeutic and medicinal properties rather than nutrition," said Meier. "While these infants are in the NICU, we have a critical window to decrease morbidity rates and risks of severe complications."

The study will follow very low birth weight infants in the Rush NICU to see what effect higher doses of human breast milk and longer periods of exposure during critical periods of hospitalization have on length of stay, infant growth, as well as lowering total NICU costs.

Infants enrolled in the study will receive different amounts of human breast milk during their NICU stay. Data on the variables of dose and exposure period of human breast milk feeding will be collected throughout the infant's entire NICU stay. Researchers also will collect data on short-term costs of providing breast milk such as breast pump rental, total number of storage containers needed and access to lactation experts.

"The findings from this study will be easily translated into health policy that we hope will help shape protocol standards for NICUs and providing care for this vulnerable patient population," said Meier.


'/>"/>

Contact: Deborah Song
deb_song@rush.edu
312-942-0588
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. Abused women seek more infant health care, MU study finds
2. New Easter Seals-MassMutual Study: Autism Strains Family Finances, Threatens Long-Term Care and Security
3. Easter Seals Study Sheds New Light on Parents Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism
4. QLT announces interim results of radical study evaluating Visudyne combination therapy
5. Newly discovered esophagus stem cells grow into transplantable tissue, Penn study finds
6. Study to identify best rehabilitation therapies for patients with traumatic brain injuries
7. Double Blind Study Proves The Pink Patch Works for Weight Loss
8. First Patient from CyberKnife Center of Palm Beach Enrolled in Worldwide Landmark Study of Operable Lung Cancer Patients
9. Planned safety analysis of a breast cancer prevention study reveals encouraging news for Exemestane
10. Genomic Health Announces Study Establishing the Utility of Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated with Aromatase Inhibitors
11. Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... , ... Most us are familiar with the sound of occasional popping joints ... Initiative shows that certain people who experience consistent joint popping, grating and grinding ... the opportunity to treat patients before the problem becomes pronounced, potentially hedging off more ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s ... Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for chronic ... introduce the most powerful SCS system and the only stretchable lead on the market. ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional Budget Office (CBO) ... House on May 4, would result in 23 million Americans losing their health insurance ... 2010 Patient Protection and Affordable Care Act (ACA). , “It is clear from ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral ... new, informational blog post on insurance options. If a Bay Area patient has to ... save time and money. Visiting an in-network provider for a second opinion can ensure ...
(Date:5/26/2017)... ... 26, 2017 , ... “Cactus Jack: Against All Odds”: the story of Coach ... Jack: Against All Odds” is the creation of published author, Walter Hubbard, a retired ... Jack Carlisle’s third child Jane. Walter. Walter and Jane have three adult children ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
(Date:5/3/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: WST), ... drug administration, announced today that Fran DeGrazio ... and Diane Paskiet , Director, Scientific Affairs, ... on West,s expertise in the areas of safety ... providing commentary on updated industry guidance. ...
Breaking Medicine Technology: